Lymphoma, Large B-Cell, Diffuse: all 1,432 studies
Page 13 of 15. Open to participants first (359), then studies with results posted, then the rest; newest registration first within each.
- Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)CompletedNCT01827579Phase 1/2
- Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin LymphomaActive, not recruitingNCT01815749Phase 1
- Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.CompletedNCT01805557Phase 2/3
- A Long-term Extension Study of PCI-32765 (Ibrutinib)Active, not recruitingNCT01804686Phase 3
- Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCLStatus unknownNCT01804127Phase 2
- A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma PatientsStatus unknownNCT01793844
- Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed LymphomasCompletedNCT01793233
- Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D InsufficiencyActive, not recruitingNCT01787409Not applicable
- A Safety Study of SGN-CD19A for B-Cell LymphomaCompletedNCT01786135Phase 1
- Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
- Dose Adjusted EPOCH-R, to Treat Mature B Cell MalignanciesCompletedNCT01760226Early Phase 1
- MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
- Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With LymphomaCompletedNCT01742988Phase 1
- Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to ChemotherapyStatus unknownNCT01735604Phase 1/2
- An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell LymphomaTerminatedNCT01724294
- Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular LymphomaCompletedNCT01722305Phase 1
- Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01719250Early Phase 1
- Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell LymphomaCompletedNCT01715961Not applicable
- A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)Status unknownNCT01676558Phase 2
- Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.Status unknownNCT01670370Phase 2
- BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and HematologyCompletedNCT01660776
- GA In NEwly Diagnosed Diffuse Large B Cell LymphomaTerminatedNCT01659099Phase 3
- Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
- STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell LymphomaStatus unknownNCT01653067Phase 2
- Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
- Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell LymphomaCompletedNCT01622439Phase 1/2
- Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell LymphomaCompletedNCT01606605
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell LymphomaCompletedNCT01563861
- Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second RelapseCompletedNCT01562990Phase 1/2
- Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCLCompletedNCT01562977Phase 2
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell LymphomaWithdrawnNCT01539174Phase 2
- Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence TrialTerminatedNCT01534949Phase 1
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid MalignanciesCompletedNCT01523223Phase 1
- Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)CompletedNCT01502982Phase 2
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- Communication Skills Intervention to Promote Transition Into SurvivorshipActive, not recruitingNCT01483664
- Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma PatientsCompletedNCT01481272Phase 2
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaActive, not recruitingNCT01479842Phase 1
- CD19 CAR T Cells for B Cell Malignancies After Allogeneic TransplantCompletedNCT01475058Phase 1/2
- SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) PatientsCompletedNCT01472887Phase 2
- Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT01470456Phase 2
- Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell LymphomaTerminatedNCT01466868Phase 2
- Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's LymphomaCompletedNCT01459887Phase 3
- Study in Patients With Primary Breast Diffuse Large B-cell LymphomaCompletedNCT01448096Phase 2
- Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)Status unknownNCT01435720Phase 1/2
- A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)WithdrawnNCT01423539Phase 2
- Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple MyelomaCompletedNCT01421524Phase 1
- MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell LymphomaWithdrawnNCT01415765Phase 1/2
- FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell LymphomaCompletedNCT01410630
- Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell LymphomaTerminatedNCT01402440Phase 1
- Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell LymphomaCompletedNCT01361191Phase 2
- Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) PatientsStatus unknownNCT01357733Not applicable
- AZD1152 in Diffuse Large B-cell LymphomaCompletedNCT01354392Phase 1/2
- An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular LymphomaCompletedNCT01340443
- Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell LymphomaCompletedNCT01334502Phase 1
- A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With BortezomibCompletedNCT01324596Phase 3
- Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With RituximabCompletedNCT01311232
- AMG 319 Lymphoid Malignancy FIHCompletedNCT01300026Phase 1
- Abbreviated R-CHOP in Completely Excised Stage I or II DLBCLStatus unknownNCT01279902Phase 2
- This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast LymphomasTerminatedNCT01279772
- R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell LymphomaStatus unknownNCT01278602Phase 2
- TREatment of degeNerative and Neoplastic Diseases With RituximabStatus unknownNCT01277172Phase 2/3
- The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT01266668
- A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT01238692Phase 2
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell LymphomaCompletedNCT01226849Phase 1
- Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell LymphomaCompletedNCT01202448Not applicable
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 YearsCompletedNCT01195714Phase 2
- Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell LymphomaStatus unknownNCT01181999Phase 2
- Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell LymphomaStatus unknownNCT01178645Phase 2
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
- 90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell LymphomaCompletedNCT01157988Phase 2
- 30Gy Versus 40Gy Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After ChemotherapyCompletedNCT01156259Phase 3
- R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCLCompletedNCT01148446Phase 3
- Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple MyelomaCompletedNCT01148108Phase 2
- Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without RituximabCompletedNCT01131208
- AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaCompletedNCT01129193Phase 1
- Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOPCompletedNCT01122472Phase 3
- Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1
- Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHLWithdrawnNCT01101581Phase 1/2
- Mini-CHOP and Rituximab in Patients Aged Over 80 YearsCompletedNCT01087424Phase 2
- DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell LymphomaStatus unknownNCT01066429Phase 2
- BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)Status unknownNCT01063439Phase 2
- Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT01054781Phase 2
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT01045928Phase 1
- Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's LymphomaStatus unknownNCT01009970Phase 2
- Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaCompletedNCT00994500Phase 1
- Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaCompletedNCT00971763Phase 2
- Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1CompletedNCT00968656Phase 1
- Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT00968331Phase 2
- Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma PatientsCompletedNCT00949741
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
- Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or LeukemiaTerminatedNCT00933985Phase 1
- Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell LymphomaStatus unknownNCT00907348Phase 2
- Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell LymphomaTerminatedNCT00906841Phase 2